Global Programme to Eliminate Lymphatic Filariasis

Global Programme to Eliminate Lymphatic Filariasis
Name	Global Programme to Eliminate Lymphatic Filariasis
Formation	1997
Founder	World Health Organization
Type	International public health campaign
Headquarters	Geneva
Region served	Global
Parent organization	World Health Organization

Global Programme to Eliminate Lymphatic Filariasis is an initiative launched by the World Health Organization in 1997 to interrupt transmission of lymphatic filariasis and alleviate suffering among affected populations. It coordinates mass drug administration, morbidity management, and surveillance across endemic countries, working with partners such as the Global Alliance to Eliminate LF, Bill & Melinda Gates Foundation, United Nations Children's Fund, and the Centers for Disease Control and Prevention. The Programme aligns with targets set by the World Health Assembly and the Sustainable Development Goals.

Background and Objectives

The Programme was established in response to the global burden documented by agencies including the World Health Organization, the World Bank, and the Global Burden of Disease Study. Its core objective is to eliminate lymphatic filariasis as a public health problem by reducing transmission through mass drug administration and managing morbidity among patients with lymphedema and hydrocele. The initiative ties into broader efforts by the United Nations and collaborations with national ministries of health in countries such as India, China, Nigeria, Brazil, and Indonesia. It also intersects with campaigns led by organizations like The Carter Center, Médecins Sans Frontières, PATH (organization), and the Rockefeller Foundation.

Strategy and Interventions

The Programme's strategy rests on two pillars: interrupt transmission through annual mass drug administration and provide morbidity management and disability prevention. Mass drug administration protocols have involved combinations of medicines donated by pharmaceutical partners including GlaxoSmithKline, Merck & Co., and Eisai Co., Ltd. using drugs such as albendazole, ivermectin, and diethylcarbamazine. Vector control measures have been coordinated with malaria and dengue initiatives led by President's Malaria Initiative, Roll Back Malaria Partnership, and local vector control programmes in cities like Lagos, Dhaka, Manila, and Bangkok. The Programme has incorporated diagnostic tools developed by research institutions such as the London School of Hygiene & Tropical Medicine, Centers for Disease Control and Prevention, and Institut Pasteur to guide decision-making.

Implementation and Global Coverage

Implementation has been decentralized to national elimination programmes in endemic countries, supported by technical agencies including the World Health Organization Regional Offices, bilateral donors like United States Agency for International Development, and philanthropic organizations such as the Bill & Melinda Gates Foundation. Large-scale campaigns have been conducted in regions spanning Sub-Saharan Africa, South-East Asia, Western Pacific, Eastern Mediterranean Region, and the Americas. Countries with major campaigns include India, Nigeria, Indonesia, Bangladesh, Egypt, Haiti, Mozambique, and Philippines. The Programme coordinates with supply chains used by UNICEF and logistical networks in ports such as Mumbai, Singapore, and Dar es Salaam.

Monitoring, Evaluation, and Certification

Monitoring relies on infection mapping, sentinel site surveillance, and transmission assessment surveys developed in consultation with partners including the World Health Organization, Centers for Disease Control and Prevention, London School of Hygiene & Tropical Medicine, and national public health institutes such as Indian Council of Medical Research and China CDC. Certification of elimination is overseen by the World Health Organization through verification dossiers submitted by national authorities and assessed by expert advisory groups composed of specialists from institutions like Harvard T.H. Chan School of Public Health, University of Oxford, and Johns Hopkins Bloomberg School of Public Health. The Programme leverages data systems used in global health, including health information platforms supported by The Global Fund, to track progress.

Challenges and Criticisms

The Programme has faced logistical, epidemiological, and financial challenges. Operational hurdles have included ensuring high treatment coverage in contexts such as conflict-affected areas like South Sudan and Syria and in settings with mobile populations across borders with Bangladesh and Myanmar. Scientific critiques have addressed issues of emerging resistance documented in studies from institutions such as University of Ghana and Mahidol University, diagnostic sensitivity concerns raised by investigators at Institut Pasteur and CDC, and the complexity of co-endemic infections with Onchocerciasis that require coordination with programmes led by The Carter Center and African Programme for Onchocerciasis Control. Donor dependency and sustainability have been debated by analysts at the World Bank and Overseas Development Institute.

Impact and Outcomes

By the mid-2020s the Programme had delivered billions of treatments and achieved validated elimination of lymphatic filariasis as a public health problem in multiple countries, with certification milestones in nations such as Tonga, Maldives, Sri Lanka, Gabon, and Cambodia. Reductions in microfilaremia prevalence and disability have been reported in studies by groups at Imperial College London, University of Washington, Liverpool School of Tropical Medicine, and national ministries of health. The Programme has influenced global health policy dialogues at forums including the World Health Assembly, Gavi, the Vaccine Alliance, and UN General Assembly special sessions, and has catalyzed integration with neglected tropical disease programmes spearheaded by entities such as the Global Network for Neglected Tropical Diseases and the Neglected Tropical Diseases NGO network (NNN).

Category:Lymphatic filariasis